The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Research Guide

Noopept
Research Guide

A Research Use Only reference to Noopept: identity data, what published studies examined, handling and storage for laboratories.

Research reference · Updated October 9, 2026 · How we check our guides

What is Noopept?

Noopept (omberacetam, also coded GVS-111) is N-phenylacetyl-L-prolylglycine ethyl ester, a small synthetic dipeptide derivative. Scientists at the V. V. Zakusov Research Institute of Pharmacology in Moscow designed it as a dipeptide analog of piracetam (Gudasheva et al., 2018), and its major metabolite in rat brain is cycloprolylglycine, a cyclic dipeptide that also occurs there naturally (Gudasheva et al., 1997).

The institute reports that it introduced Noopept into medical practice (Boyko et al., 2018); in the United States, omberacetam is not an approved drug (Cohen et al., 2021). Disguised Alpha supplies it in 20MG capsules for laboratory research use only. Nothing on this page is guidance for use in people.

Noopept reference data

PropertyValue
NameNoopept
Also calledOmberacetam (INN), GVS-111, SGS-111, N-phenylacetyl-L-prolylglycine ethyl ester (PubChem CID 180496)
StructureEthyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate: L-proline and glycine joined by a peptide bond, with a phenylacetyl group on the proline nitrogen and the glycine carboxyl group as an ethyl ester
Compound classAcyl-prolyl dipeptide derivative, designed as a peptide analog of piracetam
Molecular formulaC₁₇H₂₂N₂O₄
Molecular weight318.4 g/mol
PubChem CID180496
FormCapsules, 20MG per capsule (label strength), 60 capsules per bottle
TestingThird-party tested, with the certificate for each lot published on the product page and in the COA portal

Formula, molecular weight, capsule format, label strength and storage are from the Noopept product page; PubChem CID 180496 lists the same formula and weight and is the source of the aliases and structure. For quantitative work, use the measured content per capsule on your lot's certificate.

See it beside the other compounds on this site in the peptide molecular weight reference table.

What the research covers

Published work on Noopept falls into six areas. Each summary below states the model used. Most of it comes from the Moscow institute that developed the compound and its collaborators.

Design and metabolism

Its developers built Noopept by reproducing the structure of piracetam with a dipeptide (Gudasheva et al., 2018). One hour after rats received 5 mg/kg intraperitoneally, the parent compound was undetectable in brain while cycloprolylglycine had risen 2.5-fold, and plasma and brain enzymes formed cycloprolylglycine from it in vitro, so the authors proposed that Noopept is a prodrug (Gudasheva et al., 1997). A later rat study found that the metabolite differs from Noopept in its pharmacokinetics but has a similar spectrum of action on memory (Boyko et al., 2018). Models: rats and enzyme assays.

Rodent memory and neuroprotection models

Given orally to rats trained in passive avoidance, Noopept at 0.5 to 10 mg/kg kept its antiamnesic activity, and repeated exposure raised the number of initially unsuccessful rats that learned an active avoidance task, unlike cycloprolylglycine or piracetam (Ostrovskaya et al., 2001). After photochemical thrombosis of the rat frontal cortex, 0.5 mg/kg/day intravenously for 9 days from 1 hour after the lesion reduced the passive avoidance deficit and the infarct volume (Ostrovskaya et al., 1999).

An independent Spanish group gave it, as SGS-111, to Ts65Dn mice, a Down syndrome model, in adulthood or from conception to 5 months of age: hyperactivity fell, but cognitive deficits were not reversed, and spatial learning gains appeared only in control mice (Rueda et al., 2008). Models: rats and mice.

BDNF and NGF in rat hippocampus

In rats, Northern blot analysis showed that a single exposure raised hippocampal mRNA for NGF and BDNF and that 28 days of exposure strengthened the effect without tolerance; in the cortex, levels fell after a single exposure, and BDNF rose slightly with chronic exposure (Ostrovskaya et al., 2008). The study measured mRNA, not protein, and came from the developing laboratory. A 2021 rat study linking Noopept to spinal microglial BDNF in persistent inflammation was retracted by its journal three months after publication, so it is not evidence (Taghizadeh et al., 2021). Model: rat brain tissue.

Glutamate and oxidative stress in cell models

In cultured cerebellar granule cells, GVS-111 protected neurons from oxygen and glucose deprivation and from glutamate or oxidative stress, while piracetam did not reduce glutamate toxicity (Andreeva et al., 2000). At the University of Connecticut, with Moscow co-authors, it raised the survival of human cortical neurons exposed to hydrogen peroxide (half-maximal value 1.21 µM), lowered free radicals and lipid peroxidation, protected more than piracetam or vitamin E, and reduced degeneration in Down syndrome cortical cultures (Pelsman et al., 2003). Models: cerebellar and human cortical neuron cultures.

Amyloid models

In PC12 cells, 10 µM Noopept added 72 hours before amyloid beta 25-35 raised viability and mitochondrial membrane potential and reduced apoptosis, reactive oxygen species, intracellular calcium and tau phosphorylation at Ser396 (Ostrovskaya et al., 2014). In NMRI mice after olfactory bulbectomy, a model with Alzheimer's disease-like features, 0.01 mg/kg for 21 days restored spatial memory in the Morris water maze and raised serum antibodies to amyloid beta 25-35 oligomers, but not to lysozyme amyloid or S100b (Ostrovskaya et al., 2007). Models: PC12 cells and mice.

Human studies

The human evidence is small and regional. Nearly all human studies indexed in PubMed come from Russian centers and Russian-language journals, the two abstracts that give a size each describe 60 people, and PubMed indexes no randomized, placebo-controlled trial. The developing institute also compared Noopept with piracetam in mild cognitive disorders of vascular or traumatic origin; PubMed lists no abstract, so its outcome is not summarized here (Neznamov and Teleshova, 2009).

An open prospective study of 60 people with mild cognitive impairment after stroke reported significant gains on the MMSE and word-association tests at 2 months compared with controls (Amelin et al., 2011). A two-group study of 60 people starting tuberculosis chemotherapy reported less anxiety and fewer neurotoxic and cardiotoxic drug reactions in the 30 given Noopept (Mordyk et al., 2009). Model: human clinical studies.

Key studies

  1. Gudasheva TA, et al. "The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine." Eur J Drug Metab Pharmacokinet. 1997. PMID 9358206. DOI 10.1007/BF03189814. Rat brain: cycloprolylglycine as the major metabolite.
  2. Pelsman A, et al. "GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons." Int J Dev Neurosci. 2003. PMID 12711349. DOI 10.1016/s0736-5748(03)00031-5. Human cortical neuron cultures exposed to hydrogen peroxide.
  3. Ostrovskaya RU, et al. "Noopept stimulates the expression of NGF and BDNF in rat hippocampus." Bull Exp Biol Med. 2008. PMID 19240853. DOI 10.1007/s10517-008-0297-x. Rat hippocampal NGF and BDNF mRNA.
  4. Rueda N, et al. "Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome." Behav Brain Res. 2008. PMID 18178265. DOI 10.1016/j.bbr.2007.11.020. Independent mouse study: cognitive deficits unchanged.
  5. Ostrovskaya RU, et al. "Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation." J Biomed Sci. 2014. PMID 25096780. DOI 10.1186/s12929-014-0074-2. PC12 cells exposed to amyloid beta 25-35.
  6. Amelin AV, et al. "[Noopept in the treatment of mild cognitive impairment in patients with stroke]." Zh Nevrol Psikhiatr Im S S Korsakova. 2011. PMID 22500312. Open prospective study of 60 people after stroke.

Handling and storage of Noopept capsules

General laboratory practice for this material:

  • Store the sealed capsules at 15 to 25°C in the original sealed container, away from moisture and direct light (storage guidance on the product page).
  • Capsules ship in a sealed plastic bottle, a sealed glass bottle or a resealable pouch, depending on the batch; close it fully after each opening.
  • Record the lot number and keep its certificate with your notes. The certificate reports the measured content per capsule for that lot.
  • For identity checks, compare analytical data with the formula C₁₇H₂₂N₂O₄ and molecular weight 318.4 g/mol.

Frequently asked questions

What is Noopept?

Noopept is N-phenylacetyl-L-prolylglycine ethyl ester (PubChem CID 180496), a synthetic dipeptide derivative designed in Moscow as a peptide analog of piracetam (Gudasheva et al., 2018).

Is Noopept a peptide?

Not in the usual sense. Noopept is an N-phenylacetyl-L-prolylglycine ethyl ester, a dipeptide derivative: L-proline and glycine joined by a peptide bond, with a phenylacetyl cap on the proline nitrogen and an ethyl ester in place of the free acid. Its developers named it from the words nootropic and peptide (Gudasheva et al., 2018), but at 318.4 g/mol it is far smaller than most research peptides.

What is omberacetam?

Omberacetam is the International Nonproprietary Name for Noopept. PubChem (CID 180496) and the FDA's substance registry (UNII 4QBJ98683M) list Noopept and GVS-111 as synonyms; the registry notes that a UNII does not imply regulatory review or approval.

Is Noopept approved by the FDA?

No. Omberacetam is not an approved drug in the United States (Cohen et al., 2021). The FDA sent warning letters in 2019 and 2022 to sellers whose Noopept products carried Alzheimer's disease claims, calling them unapproved new drugs. In a test of 10 cognitive supplements bought online, omberacetam was among five unapproved drugs detected, and 9 of 12 declared quantities were inaccurate (Cohen et al., 2021).

Has Noopept been tested in people?

Yes, as research history, in small studies from Russian centers, such as an open study after stroke (Amelin et al., 2011). PubMed indexes no randomized, placebo-controlled trial.

How should Noopept capsules be stored?

Keep them sealed in the original container at 15 to 25°C, away from moisture and direct light, as listed on the product page.

Where can researchers buy Noopept?

Disguised Alpha sells Noopept for laboratory research as 20MG capsules, 60 per bottle, third-party tested with the certificate for each lot published on the product page: Noopept. Two aerosol blends that contain it are listed separately: CogniWell and Limitless.

Related compounds and guides

This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.

Certificates of analysis

Each tested batch of Noopept has its own certificate page with the full lab results.

25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop